Information about Taliglucerase alfa
Taliglucerase (tal" i gloo' ser ase) alfa was the third recombinant form of glucocerebrosidase approved for therapy of type 1 Gaucher disease. Taliglucerase is prepared in plant cell cultures transfected with the human glucocerebrosidase gene. Taliglucerase differs from the native enzyme by two amino acids at the N terminal and 7 amino acids at the C terminal end. It is glycosylated and the oligosaccharide chains have terminal mannose sugars, which increase its uptake by macrophages.
FDA approval information for Taliglucerase alfa
Taliglucerase was approved for use as enzyme replacement therapy for type 1 Gaucher disease in the United States in 2011. It is available as lyophilized powder in single use vials of 200 Units.
Dosage and administration for Taliglucerase alfa
The typical dose is 60 Units/kg every two weeks administered intravenously over 1 to 2 hours.
Side effects of Taliglucerase alfa
Side effects are not common and usually mild, but can include local infusion reactions, fatigue, headache, dizziness, abdominal pain, nausea, back pain, joint pain and fever. Rare, but reported severe adverse reactions include hypersensitivity reactions and anaphylaxis.
genetic disorder agents
- gaucher disease agents
glucosylceramide synthase inhibitors (substrate restriction therapy)
lysosomal acid lipase deficiency agents
- agalsidase beta, alglucosidase alfa, alpha1-proteinase inhibitor, elosulfase alfa, galsulfase, idursulfase, laronidase, pegademase
Huntington disease agents
Urea Cycle Disorder Agents